Sanofi

🇫🇷France

Country: 🇫🇷France

Ownership: Public

Employees: 87.9K

Market Cap: $141.3B

Website: http://www.sanofi.com

Introduction: Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.

Clinical Trials

Cognitive Status, Fatigue and Inflammation in Patients With Immune Thrombocytopenia (ITP)

Recruiting

Conditions: Chronic Immune Thrombocytopenia
Primary Immune Thrombocytopenia
Adult Immune Thrombocytopenia

First Posted Date: 2024-10-30

Last Posted Date: 2025-04-02

Lead Sponsor: Sanofi

Target Recruit Count: 110

Registration Number: NCT06665308

Locations: 🇺🇸
Massachusetts General Hospital- Site Number : 8400001, Boston, Massachusetts, United States
🇬🇧
Investigational Site Number: 8260001, London, City Of London, United Kingdom
🇺🇸
USC Norris Comprehensive Cancer Center- Site Number : 8400002, Los Angeles, California, United States

and more 1 locations

A Safety and Efficacy Study of One-time SAR402663 in Adults With Neovascular Age-related Macular Degeneration

Phase 1

Recruiting

Conditions: Neovascular Age-related Macular Degeneration

Interventions: Biological: SAR402663
Drug: Diluent

First Posted Date: 2024-10-28

Last Posted Date: 2025-04-04

Lead Sponsor: Sanofi

Target Recruit Count: 66

Registration Number: NCT06660667

Locations: 🇺🇸
Site # 8400023, Beverly Hills, California, United States
🇺🇸
Site # 8400017, Eugene, Oregon, United States
🇺🇸
Site # 8400021, Reno, Nevada, United States

and more 6 locations

A Study to Investigate Efficacy and Safety of SAR441566 in Patients With Crohn's Disease.

Phase 2

Recruiting

Conditions: Crohn's Disease

Interventions: Drug: SAR441566
Drug: SAR441566 matching Placebo

First Posted Date: 2024-10-15

Last Posted Date: 2025-05-20

Lead Sponsor: Sanofi

Target Recruit Count: 260

Registration Number: NCT06637631

Locations: 🇦🇷
Investigational Site Number : 0320002, San Miguel de Tucumán, Tucumán, Argentina
🇦🇷
Investigational Site Number : 0320001, Buenos Aires, Argentina
🇧🇷
Hospital Moinhos de Vento- Site Number : 0760006, Porto Alegre, Rio Grande Do Sul, Brazil

and more 62 locations

A Study to Investigate the Safety and Efficacy of SAR446523 Injected Subcutaneously in Adult Participants With Relapsed/Refractory Myeloma

Phase 1

Recruiting

Conditions: Plasma Cell Myeloma Refractory

Interventions: Drug: SAR446523

First Posted Date: 2024-10-08

Last Posted Date: 2025-04-23

Lead Sponsor: Sanofi

Target Recruit Count: 82

Registration Number: NCT06630806

Locations: 🇮🇱
Investigational Site Number : 3760001, Tel Aviv, Israel
🇮🇹
Investigational Site Number : 3800001, Rozzano, Milano, Italy
🇮🇹
Investigational Site Number : 3800002, Torette, Ancona, Italy

and more 6 locations

A Clinical Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Belumosudil in Chinese Adolescents With cGVHD Who Have Had an Inadequate Response to Glucocorticoids or Other Systemic Therapies

Phase 4

Recruiting

Conditions: Chronic Graft Versus Host Disease

Interventions: Drug: Belumosudil

First Posted Date: 2024-09-27

Last Posted Date: 2024-12-06

Lead Sponsor: Sanofi

Target Recruit Count: 6

Registration Number: NCT06616415

Locations: 🇨🇳
Investigational Site Number: 1560001, Beijing, China
🇨🇳
Investigational Site Number: 1560002, Shanghai, China

Long-term Safety and Efficacy Evaluation of Lunsekimig (SAR443765) in Adult Participants With Moderatetosevere Asthma.

Phase 2

Recruiting

Conditions: Asthma

Interventions: Drug: Lunsekimig

First Posted Date: 2024-09-24

Last Posted Date: 2025-05-14

Lead Sponsor: Sanofi

Target Recruit Count: 530

Registration Number: NCT06609239

Locations: 🇺🇸
Allianz Research Institute CO- Site Number : 8400026, Aurora, Colorado, United States
🇺🇸
Western States Clinical Research- Site Number : 8400014, Wheat Ridge, Colorado, United States
🇺🇸
Qway Research - Hialeah- Site Number : 8400015, Hialeah, Florida, United States

and more 32 locations

A Phase 2a/b Study of the Efficacy and Safety of Subcutaneous Amlitelimab in Adults With Nonresponsive Celiac Disease

Phase 2

Recruiting

Conditions: Coeliac Disease
Celiac Disease

Interventions: Drug: Amlitelimab
Drug: Placebo
Dietary Supplement: Gluten-free product (GFP)
Dietary Supplement: SIGE

First Posted Date: 2024-08-16

Last Posted Date: 2025-05-21

Lead Sponsor: Sanofi

Target Recruit Count: 204

Registration Number: NCT06557772

Locations: 🇦🇷
Investigational Site Number : 0320012, Buenos Aires, Argentina
🇹🇷
Investigational Site Number : 7920003, Gaziantep, Turkey
🇺🇸
FOMAT Medical Research - inSite Digestive Health Care - Arcadia- Site Number : 8400052, Arcadia, California, United States

and more 98 locations

Goal Attainment and Physical Activity in People With Hemophilia A

Recruiting

Conditions: Hemophilia A

Interventions: Drug: efanesoctocog alfa

First Posted Date: 2024-07-31

Last Posted Date: 2025-02-03

Lead Sponsor: Sanofi

Target Recruit Count: 35

Registration Number: NCT06530030

Locations: 🇺🇸
Bleeding and Clotting Disorders Institute, Peoria, Illinois, United States

A Study to Investigate Natural Killer Cell Engager (SAR443579) With Different Agents in Participants With Hematological Malignancies

Phase 1

Recruiting

Conditions: Acute Myeloid Leukemia

Interventions: Biological: SAR443579
Drug: venetoclax
Drug: azacitidine

First Posted Date: 2024-07-18

Last Posted Date: 2025-03-20

Lead Sponsor: Sanofi

Target Recruit Count: 18

Registration Number: NCT06508489

Locations: 🇺🇸
City of Hope National Medical Center- Site Number : 8400003, Duarte, California, United States
🇺🇸
Montefiore Medical Center- Site Number : 8400004, Bronx, New York, United States
🇺🇸
The Ohio State University Wexner Medical Center - Ohio State Outpatient Care Upper Arlington- Site Number : 8400001, Columbus, Ohio, United States

and more 4 locations

A Study to Evaluate the Efficacy and Safety of Frexalimab, SAR442970, or Rilzabrutinib in Participants Aged 16 to 75 Years With Primary Focal Segmental Glomerulosclerosis or Minimal Change Disease

Phase 2

Recruiting

Conditions: Glomerulonephritis Minimal Lesion
Focal Segmental Glomerulosclerosis

Interventions: Drug: frexalimab
Drug: SAR442970
Drug: rilzabrutinib
Drug: placebo

First Posted Date: 2024-07-15

Last Posted Date: 2025-05-09

Lead Sponsor: Sanofi

Target Recruit Count: 84

Registration Number: NCT06500702

Locations: 🇪🇸
Investigational Site Number : 7240002, Córdoba, Spain
🇪🇸
Investigational Site Number : 7240003, Valencia, Spain
🇺🇸
Investigational Site Number : 8400015, Orange, California, United States

and more 36 locations

Home Terms & Conditions Privacy Policy